Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme-Reference-Cited by-同舟云学术

Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme

Published:2021-07 Issue:4 Volume:22 Page:332-340.e3
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Regnery Sebastian^ORCID,Eichkorn Tanja,Weykamp Fabian^ORCID,Held Thomas,Weusthof Katharina^ORCID,Dinges Lisa-Antonia,El-Shafie Rami A.,Winter Hauke,Thomas Michael,Debus Jürgen,Adeberg Sebastian,Hörner-Rieber Juliane

Funder

Heidelberg University, Faculty of Medicine

Accuray International Sàrl

CRI – The Clinical Research Institute GmbH

View Ray Inc

Accuray Incorporated

RaySearch Laboratories AB

Vision RT limited

Astellas Pharma GmbH

Astra Zeneca GmbH

Solution Akademie GmbH

Ergomed PLC Surrey Research Park

Siemens Healthcare GmbH

Quintiles GmbH

Pharmaceutecal Research Associates GmbH

Boehringer Ingelheim Pharma GmbH Co

PTW-Freiburg Dr. Pychlau GmbH

Nanobiotix A.A

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis;Nanda;Cancer,2015

2. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer;Timmerman;J Clin Oncol,2006

3. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review;Kobiela;Crit Rev Oncol Hematol,2018

4. Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT;Hörner-Rieber;Clin Lung Cancer,2019

5. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy;Sharma;Radiother Oncol,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results;Journal of Thoracic Oncology;2024-09

2. Magnetresonanz-geführte adaptive stereotaktische Radiotherapie von Lungentumoren in ultrazentraler Lokalisation (MAGELLAN, ARO 2021-3);Die Onkologie;2024-08-09

3. Stereotactic radiotherapy for ultracentral lung tumours;Cancer/Radiothérapie;2023-09

4. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines;Lung Cancer;2023-08

5. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience;Current Problems in Cancer;2023-06